[Health Technology Assessment on diagnostic testing: Cardiac MRI and MRSA genetic testing (Real-time polymerase chain reaction)]
Ahn J, Lee S, Ko MJ, Choi M, Kim Y, Park J, Suh JK, Tchoe H, An J, Hwang JI
Record ID 32014001106
Korean
Original Title:
의료기술평가관점에서 진단 및 검사의 근거평가 : 심장 MRI 검사와 MRSA 유전자 검사(실시간중합효소연쇄반응)를 중심으로
Authors' recommendations:
This study aimed to provide basic data for a future evaluation system of non-covered diagnosis and examination items to assess them from a medical technology assessment perspective. Two examples were selected regarding the assessment of the cardiac MRI test and the MRSA genetic test (real-time polymerase chain reaction) by motoring domestic policy trends and through consultation on clinical demands with the related academic societies. A systemic review of existing literature and an economic feasibility assessment were used as the study methods.
In conclusion, In terms of the cost-effectiveness, the heart MRI test is usually more cost-effective than SPECT in the diagnosis of patients with suspected coronary artery disease (CAD), but it was found to be less cost-effective than echocardiogram.
MRSA genetic testing shows high quality of diagnostic accuracy.
For economic evaluation, this study targeted all patients who stayed for more than 48 hours since being newly admitted to the intensive care unit (ICU). A comparative analysis was conducted on the two MRSA test methods-a PCR-based test and a traditional culture-based test. A cost-effect analysis was carried out in consideration of the accuracy of each test method from the health insurance system perspective. Considering the Korean cost-effectiveness standard of 20 million/30 million KRW (J Ahn et al., 2010: J Ahn et al., 2013), it was considered to be highly cost-effective.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=134
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
South Korea
MeSH Terms
- Humans
- Cost-Benefit Analysis
- Coronary Artery Disease
- Magnetic Resonance Imaging
- Methicillin-Resistant Staphylococcus aureus
- Genetic Testing
- Polymerase Chain Reaction
Contact
Organisation Name:
National Evidence-based healthcare Collaborating Agency
Contact Address:
National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name:
int@neca.re.kr
Contact Email:
int@neca.re.kr
Copyright:
National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.